Abstract
As triple-negative breast cancers are associated with earlier recurrences and poorer survival, optimal treatment of early-stage breast cancer is essential. Several retrospective studies in triple-negative breast cancer have reported conflicting results in overall survival in patients receiving neoadjuvant or adjuvant systemic therapy. This study aims to analyze outcomes of adjuvant versus neoadjuvant in patients with early-stage triple-negative breast cancer with and without BRCA germline mutations. Patients with stage I or II triple-negative breast cancer who had BRCA testing were identified from a prospective cohort study of 4027 patients. Clinical, demographic, genetic test results, chemotherapy, recurrence, and survival data were analyzed. Overall survival and disease-free survival were estimated using the Kaplan-Meier method. 319 patients with stage I and II triple-negative breast cancer who met eligibility criteria were included in the analysis. 187 received adjuvant chemotherapy (58.6%) and 132 received neoadjuvant chemotherapy (41.4%). 135 were BRCA positive (42.3%) and 184 were BRCA negative (57.7%). There was no significant association between overall survival or disease-free survival and treatment with neoadjuvant ve...Continue Reading
References
Jan 5, 2002·Journal of the National Cancer Institute. Monographs·N WolmarkB Fisher
Feb 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Priya RastogiNorman Wolmark
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
Jul 6, 2010·The Journal of Surgical Research·Carlie R KennedyJulie A Margenthaler
Jul 9, 2010·Lancet·Andrew TuttJames Carmichael
Aug 25, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Janice S KwonBanu Arun
Jul 5, 2011·Annals of Surgical Oncology·Carla S FisherJulie A Margenthaler
Sep 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Banu ArunConstance Albarracin
May 23, 2012·Cancer·Anne-Renee HartmanJohn F Sandbach
Jun 6, 2012·PloS One·Peter MeyerBeyhan Ataseven
Aug 27, 2013·Annals of Surgical Oncology·Rachel GreenupE Shelley Hwang
May 9, 2014·Breast Cancer Research and Treatment·Priyanka SharmaAndrew K Godwin
Aug 19, 2014·Breast Cancer Research and Treatment·T ByrskiS A Narod
Jul 15, 2016·The New England Journal of Medicine·Hope S RugoUNKNOWN I-SPY 2 Investigators
Oct 16, 2016·Future Oncology·Steven J IsakoffStacie P Shepherd
Mar 31, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George SomloJeffrey N Weitzel
Jun 6, 2017·The New England Journal of Medicine·Mark RobsonPierfranco Conte
Jul 18, 2017·JAMA Oncology·Eric HahnenRita K Schmutzler
Citations
Nov 21, 2019·International Journal of Cancer. Journal International Du Cancer·Wolfgang S LiebAngelika Hausser
Sep 20, 2019·PloS One·Nusayba A BagegniFoluso O Ademuyiwa
Jan 19, 2019·Oncology Letters·Ganiou Assani, Yunfeng Zhou
Oct 7, 2018·Medicine·Houpu YangYuan Peng
Nov 9, 2018·Oncotarget·Ganiou AssaniYunfeng Zhou
Apr 10, 2019·Hereditary Cancer in Clinical Practice·Olga CarameloTeresa Almeida-Santos
Sep 10, 2019·Tumori·Lucia MangonePaolo Giorgi Rossi
Jun 17, 2020·World Journal of Surgical Oncology·Lin-Yu XiaXiao-Shi Li
May 19, 2020·The Journal of Surgical Research·Trista J Stankowski-DrenglerHeather B Neuman
Jul 3, 2021·Diagnostics·Piotr KedzierawskiStanislaw Gozdz
Sep 27, 2019·ACS Applied Materials & Interfaces·Yang DongYourong Duan